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NSAIDs have been associated with hepatorenal syndrome, a serious and often fatal complication associated
with acute decline in renal function in the context of cirrhosis. However, renal safety of selective cyclo-
oxygenase-2 (COX-2) and non-selective COX inhibitors has not been well delineated in current research with
regards to patients with cirrhosis. This literature review seeks to compare the renal safety of selective and non-
selective COX inhibitors in patients with cirrhosis.
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study was evaluated using the Grading of Recommendations, Assessments, Development and Evaluation
(GRADE) system.
Results: Selective COX-2 inhibitor did not produce statistically significant decrements in renal function,
whereas short-term use of non-selective COX inhibitors (or NSAIDs) produced significant decreases in GFR,
creatinine clearance, prostaglandin E2 levels, platelet aggregation and concurrent furosemide diuresis.
However, these adverse renal effects are also largely reversible upon cessation of NSAID use.
Conclusion: Selective COX-2 inhibitors comparatively caused less renal dysfunction and interference with
platelet function and diuretic therapy than non-selective COX inhibitors and may be safer in patients with
cirrhosis.
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Abstract   
 
Background:  Nonsteroidal anti-inflammatory drugs (NSAIDs) have been known to cause renal 
dysfunction in healthy patients and more pronounced renal effects in patients with cirrhosis and 
ascites. The use of NSAIDs have been associated with hepatorenal syndrome, a serious and often 
fatal complication associated with acute decline in renal function in the context of cirrhosis. 
However, renal safety of selective cyclo-oxygenase-2 (COX-2) and non-selective COX 
inhibitors has not been well delineated in current research with regards to patients with cirrhosis. 
This literature review seeks to compare the renal safety of selective and non-selective COX 
inhibitors in patients with cirrhosis.  
 
Methods:  A thorough multi-database search was conducted using various combinations of 
keywords. Each study was evaluated using the Grading of Recommendations, Assessments, 
Development and Evaluation (GRADE) system. 
 
Results: Selective COX-2 inhibitor did not produce statistically significant decrements in renal 
function, whereas short-term use of non-selective COX inhibitors (or NSAIDs) produced 
significant decreases in GFR, creatinine clearance, prostaglandin E2 levels, platelet aggregation 
and concurrent furosemide diuresis. However, these adverse renal effects are also largely 
reversible upon cessation of NSAID use. 
 
Conclusion: Selective COX-2 inhibitors comparatively caused less renal dysfunction and 
interference with platelet function and diuretic therapy than non-selective COX inhibitors and 
may be safer in patients with cirrhosis.  
 
Keywords:  Renal dysfunction, renal failure, NSAID, COX inhibitor, celecoxib, ibuprofen, 
naproxen, sulindac, cirrhosis, ascites, liver dysfunction  
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Renal Dysfunction with Use of Nonsteroidal Anti-Inflammatory Drugs in 
Patients with Cirrhosis 
 
BACKGROUND 
Anti-inflammatory and analgesic use in patients with cirrhosis have been challenging 
clinically. Currently no guidelines have been established on pain management in patients with 
liver dysfunction and cirrhosis. The analgesic of choice is acetaminophen at reduced maximum 
daily dose of 2-3 g/day, however acetaminophen does not address anti-inflammatory needs.1 On 
the other hand, non-steroidal anti-inflammatory drugs (NSAIDS) is less safe due to concerns of 
causing renal dysfunction or more severely, hepatorenal syndrome (HRS), through inhibition of 
production of renal-protective prostaglandins. Hepatorenal syndrome is a serious, albeit 
preventable and reversible complication of cirrhosis, characterized by renal dysfunction in 
advanced hepatic fibrosis, and often precipitated by conditions that impair renal function, such as 
NSAID use, dehydration, hypovolemia, or bacterial infections. Adverse drug reactions affecting 
renal derangements are especially pronounced in patients with cirrhosis and ascites.2-4 
Hepatorenal syndrome can be rapidly progressive, highly fatal (type 1), or may present with 
relatively more stable clinical conditions and longer survival (type 2).3 The etiology behind renal 
dysfunction in cirrhosis mainly involves vasoconstriction of renal arteries, commonly associated 
with use of ibuprofen, indomethacin, naproxen, sulindac and lysine-acetylsalicylate. 
Vasoconstriction of renal arteries, from the inhibition of vasodilating prostaglandins, decreases 
perfusion to the kidneys and, as a result, also decreases the glomerular filtration rate (GFR).2,5 
Current literature is ambivalent about the renal effects of COX-2 inhibitors, whereas 
renal impairments from non-selective COX inhibitors have been well described.6-10 Some results 
suggested that both COX-2 inhibitors (rofecoxib, celecoxib) and a non-selective COX inhibitor 
(naproxen) caused a significant decline in urinary sodium from baseline in previously healthy 
elderly subjects,11 whereas another study identified significant increases in serum creatinine in 
prerenal azotemic patients taking a non-selective COX inhibitors (ibuprofen or diclofenac) but 
not a COX-2 inhibitor (celecoxib).12 In addition to a question of safety to the renal system, 
NSAIDs have also been associated with inhibition of platelet function and interference with 
diuretics, both of which can lead to serious complications in cirrhosis such as esophageal 
variceal bleeding, ascites, and edema.13-16 See Table 1 for a list of selective and non-selective 
COX inhibitors. This literature review seeks to compare renal effects of selective COX-2 and 
non-selective COX inhibitors in the context of cirrhosis. 
 
METHODS 
A systematic search for relevant studies and articles was conducted using various 
combinations of the following keywords: “NSAID,” “COX-II inhibitor,” “non-selective COX 
inhibitor,” “anti-inflammatory,” “celecoxib,” “ibuprofen,” “naproxen,” “cirrhosis,” “ascites,” 
“liver failure,” “renal dysfunction,” “hepatorenal syndrome,” “controlled trial,” and “pain 
management.”  Articles were identified using Medline (PubMed and Ovid), CINAHL, Web of 
Science, and Google Scholars. References of pertinent articles also served as sources of 
information, indirectly linking the search to other articles not otherwise identified using the 
keywords listed above. The inclusion criteria included studies investigating the use of selective 
COX-II and/or non-selective NSAIDs in patients with cirrhosis. Exclusion criteria included 
studies in animal subjects, isolated case reports, studies involving patients without liver 
dysfunctions, studies of patients with prior history of hepatorenal syndrome or renal 
insufficiency, and articles not available in digital format and required additional payment to 
request through inter-institutional library system.  
Each study was evaluated for quality of study design and quality of evidence using the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, 
which downgrades the level of evidence based on limitations, indirectness, imprecision, 
inconsistency, and publication bias.17 Based on quality of evidence, strength of recommendation 
is assigned to describe the impact of results, either as a strong or weak recommendation. 
 
RESULTS 
A thorough search in different databases generated a total of 31 relevant articles, with at 
least two keywords in the topic. A total of 6 studies met eligibility criteria and are included in 
this review. One study,8 a randomized control study, compared a selective COX-2 inhibitor, a 
non-selective COX inhibitor, and placebo. A pilot study18 only evaluated a selective COX-2 
inhibitor.  While, the four remaining studies6,7,9,10 measured the renal effects of non-selective 
COX inhibitors. See Tables 3 and 4 for quality assessment of the studies and outcomes using the 
GRADE system. 
 
Selective COX-2 Inhibitors in Cirrhotic Patients 
In Claria et al8 a double-blind, randomized, placebo-controlled trial was conducted to 
investigate the effect of celecoxib, naproxen and placebo on renal function in patients with 
cirrhosis without previous hepatorenal syndrome.  Twenty-eight patients with compensated 
cirrhosis and ascites were randomly assigned to receive short-term, twice-daily and anti-
inflammatory dosing of celecoxib (COX-2 selective inhibitor), naproxen (non-selective COX 
inhibitor), or placebo for a total of 5 doses, each with simultaneous oral use of furosemide. 
Randomization to treatment was determined by a random number generator. All investigators 
and subjects were blinded to sequence allocation, and all medications including placebo were 
manufactured by an independent pharmaceutical company to appear similarly. Subjects eligible 
for the study had met the criteria of diagnosis of cirrhosis, serum creatinine less than 1.5mg/dL, 
and without hepatic encephalopathy, bacterial infections, cardiorespiratory diseases, renal 
diseases, type 1 diabetes mellitus, peripheral vascular disease, hepatocellular carcinoma, 
treatment with beta-blockers, and history of peptic ulcer or gastrointestinal bleeding. Seven 
subjects were excluded from analysis after GFR measured below 40 mL/min. Data was analyzed 
using one-way analysis of variance and unpaired Student t tests. Baseline markers and 
parameters of liver, platelet aggregation, and renal functions were measured after a four-day 
wash-out period of all NSAIDs and diuretics.8  
 The results demonstrated no statistically significant derangements in GFR, urinary 
prostaglandin E2 (PGE2), renal plasma flow (RPF), inhibition of platelet aggregation (PA), and 
interference with efficacy of furosemide diuresis (Vfurosemide) were observed in the group treated 
with celecoxib or placebo, whereas the naproxen group showed statistically significant 
differences which are discussed in the next section. (See Table 2 for more detailed data.) The 
study concluded that celecoxib was renal-sparing, with effects similar to that of placebo, and 
safer than naproxen in patients with cirrhosis and ascites.8  
In a second study, effects of short-term use of celecoxib on renal function described by 
Guevara et al18 in a pilot quasi-experimental study, which included 9 patients with cirrhosis and 
ascites. No randomization or blinding was described. Patients with BUN > 40mg/dL, serum 
creatinine > 1.5 mg/dL, low platelet count, and gastrointestinal bleeding were excluded from the 
study. All patients were placed on a controlled sodium diet of 50 mEq per day for 5 days prior, 
followed by a treatment with celecoxib 200 mg once daily for 5 consecutive days. In analyzing 
data, the non-parametric Wilcoxin test was utilized, which demonstrated no statistical 
significance in change in creatinine (0.7 ± 0.06 versus 0.8 ± 0.04 mg/dL) from baseline. 
Moreover, results demonstrated no significant reductions prior to and after treatment in GFR (74 
± 8 to 67 ± 8 mL/min), PGE2 (1429 ± 265 to 1053 ± 224 pg/min), PG 6-keto-F1α (2021 ± 298 to 
1400 ± 269 pg/mL), urine sodium (4 ± 4 to 8 ± 6 mEq/L), and urine volume (1115 ± 87 to 1083 
± 89 mL/day) with short-term use of celecoxib. However, a decline in GFR of at least 20% was 
observed in 4 out of 9 patients. The conclusions of the pilot study suggested no renal dysfunction 
with short-term administration of 200 mg daily dose of celecoxib in patients with cirrhosis and 
ascites.18  
 
Non-selective COX inhibitors in cirrhotic patients  
As mentioned earlier, effects of naproxen were compared to celecoxib and placebo in a 
randomized controlled trial conducted by Claria et al.8 Findings of the study include statistically 
significant reduction in GFR in the group treated with naproxen (500mg BID for 5 doses), p < 
0.05. Also, urinary PGE2, a marker for homeostatic control of renal vasodilatation and perfusion, 
was significantly reduced in the naproxen treatment group and spared in the celecoxib and 
placebo groups. Reduced renal plasma flow, inhibition of platelet aggregation, and dampened 
response to the diuretic furosemide measured in terms of urine volume were also demonstrated 
after 5 doses of naproxen and not in the other two groups. (See Table 2.) The study concluded 
that naproxen greatly affected renal function on a short-term course and should be avoided or 
used with great caution in patients with cirrhosis.8  
Similar renal impairments were demonstrated in a randomized trial7 conducted by Brater 
et al in 1987, concerning the acute and chronic use of sulindac, ibuprofen and naproxen in 5 
patients with cirrhosis. Subjects who had documented cirrhosis with ascites and no more than 
trace edema were recruited. All 5 patients were placed on a controlled sodium diet for 3 days, 
after which baseline blood and urine samples were obtained. All 5 patients received a single dose 
of sulindac 200mg. Also depending on tolerability, 4 out of 5 patients proceeded to receive a 
regimen of twice daily dosing of sulindac for 4 more days. One patient withdrew due to 
intolerance and health problems. Then an unspecified randomization scheme was utilized to 
assign patients to receive either ibuprofen or naproxen following a 5-day recovery period with 
sulindac use. Four patients continued to receive a single dose of either ibuprofen 600mg or 
naproxen 500mg. Two of four subjects tolerated without drastic decrements in creatinine 
clearance and continued on with thrice daily dosing of ibuprofen or twice daily dosing of 
naproxen for 4 more days. Four out of five patients experienced reduction in creatinine clearance 
after a single dose of sulindac. Two of four patients had significantly decreased creatinine 
clearance (116 ± 6.7 to 90 ± 3.0 mL/min, p-value < 0.05; 111 ± 5.9 to 89 ± 2.2 mL/min, p-value 
<0.05) with 4 additional days of exposure to sulindac.  Two of two patients receiving additional 
doses of ibuprofen also experienced significant reduction in creatinine clearance (93 ± 3.6 to 78 
± 0.9 mL/min, p-value < 0.05; 111 ± 5.9 to 87 ± 4.6 mL/min, p-value <0.05). Interestingly, all 
patients except the withdrawn participant recovered from impairments in creatinine clearance 
after a 5-day recovery period post-treatment. This suggests derangements in renal function 
associated with non-selective COX inhibitors can be acute and largely reversible.7  
A quasi-experimental study conducted by Daskalopoulos et al9 investigated effects of 
indomethacin and sulindac on renal function and response to furosemide in 15 patients with 
cirrhosis. Patients were confirmed to have cirrhosis on liver scan, biopsy or other standard 
criteria. Nine patients received sulindac 150mg orally, while 3 of the patients in sulindac group 
and 6 more received indomethacin 50mg orally, summing to 9 in the indomethacin group. On 
day three, all patients received furosemide IV for evaluation of response to diuretics. A 5-day 
washout period and controlled sodium diet were implemented before receiving treatment. No 
randomization or control group was in place.  The indomethacin treatment group demonstrated 
significant reduction from basal measurements in urinary volume (90 ± 21 to 16 ± 5 mL/h, p-
value < 0.05), creatinine clearance (99 ± 18 to 45 ± 10 mL/min, p-value < 0.05), and urinary 
PGE2 (27.9 ± 6.6 to 3.7 ± 1.1 ng/h, p-value < 0.01), whereas the sulindac treatment group did 
not show statistically significant reductions in the corresponding parameters. Both the sulindac 
and indomethacin groups showed significantly diminished response to furosemide diuresis in 
urinary volume and urine sodium. Urinary volume in the group treated with both furosemide and 
sulindac decreased from 365 ± 114 to 227 ± 151 mL/h, p-value < 0.05, and urinary sodium 
declined from 124 ± 60 to 60 ± 36 mEq/h, p-value < 0.05. Results of from the group treated with 
indomethacin and furosemide showed a mean reduction in urinary volume, from 290 ± 50 to 130 
± 54 mL/h, p-value < 0.01, and urinary sodium from 84 ± 28 to 28 ± 24 mEq/h, p-value < 0.05. 
Moreover, PGE2 levels decreased significantly after administration of sulindac and furosemide 
(p-value < 0.05) and indomethacin and furosemide (p-value < 0.02). Both medications impaired 
renal function and response to furosemide. Effects are more pronounced with indomethacin than 
sulindac on suppression of renal functions. 9  
Another quasi-experimental study by Quintero et al19 measured the effects of short-term 
use of sulindac on renal function in patients with cirrhosis and ascites arrived at similar 
conclusions. Quintero et al measured GFR, free water clearance, PGE2
 
and PG 6-keto-EF1α in 5 
non-azotemic patients with cirrhosis and ascites before and after 3 days of sulindac 200mg twice 
daily dosing. No randomization or blinding was in place. Patients were placed a controlled 
sodium diet consisting of 50 mEq of sodium daily, and a 6-day wash-out period of NSAIDs, 
diuretics, and other medications. In addition, 6 healthy volunteers served as control for 
comparing serum levels of sulindac sulfide and sulindac sulfone, metabolites of sulindac. Results 
showed significant, across-the-board reductions after sulindac treatment in mean GFR (111 ± 15 
to 67 ± 10 mL/min; p-value < 0.01), free water clearance (7.0 ± 1.5 to 3.7 ± 1.3; p-value < 0.02), 
urine volume (10.8 ± 1.8 to 6.3 ± 1.6 mL/min; p-value < 0.02), urine PGE2 (24.2 ± 5.5 to 3.8 ± 
1.1 ng/h; p-value < 0.05), and PG 6-keto-EF1α (19.9 ± 2.9 to 5.6 ± 1.1 ng/h; p-value < 0.02). 
Additionally, serum levels of sulindac and sulindac sulfide were found to be four times higher 
than in healthy subjects, (p-value < 0.01). Quintero et al concluded that sulindac at 200mg twice 
daily, the recommended dosing for anti-inflammatory needs, produced marked impairments in 
GFR and production of renal prostaglandin in patients with cirrhosis and ascites, and thus 
monitoring is needed when administering sulindac and/or other NSAIDs.19  
An earlier study by Brater et al6 conducted in 1986, 5 patients with cirrhosis in a quasi-
experimental study were placed on a controlled sodium diet and diuretic washout-period for 5 
days. Patients were confirmed to have no history of or concurrent renal insufficiency, and 
received a single 200mg dose of sulindac. Renal parameters were monitored for 4 or 5 additional 
days following treatment with sulindac for safety. Four patients experienced a transient decrease 
in creatinine clearance immediately after dose of sulindac, measured using inulin clearance. 
Mean creatinine clearance was 58.2 mL/min; however, statistical significance, standard error, 
and confidence intervals were not calculated. The reduction in creatinine clearance averaged 47.5% 
among the 4 patients. Creatinine clearance recovered to pre-treatment levels after a second 
assessment 6 to 8 hours post-administration of sulindac. Brater et al concluded that sulindac 
produced the similar renal impairments as previously reported with other NSAIDs and should be 
used with caution.6  
 
DISCUSSION 
Renal Dysfunction in Non-Selective COX and Selective COX-2 Inhibitors 
Findings from the studies suggest that non-selective COX inhibitors markedly reduce 
renal function for the duration of use, however impairments are less pronounced in selective 
COX-2 inhibitors. Specifically, the reductions in creatinine clearance and/or GFR and 
prostaglandin levels were significantly more than levels corresponding to the use of selective 
COX-2 inhibitors. Although the level of evidence in the safety of selective COX-2 inhibitors in 
cirrhosis is immensely limited (see Tables 3 and 4), based on studies presented, selective COX-2 
inhibitors likely affect renal function to a lesser extent than non-selective COX inhibitors. There 
does not appear to be a dose-dependent impairment from selected data. This finding suggests a 
potential role for selective COX-2 inhibitors administered for a limited course to address anti-
inflammatory and analgesic needs in patients with cirrhosis.  
 
Reversibility of Renal Impairment, Suppression of Furosemide and Platelet Aggregation 
Secondary findings indicate that the suppressant effects on renal hemodynamics appear to 
be reversible upon termination of use of non-selective COX inhibitors, signified by recovery of 
creatinine clearance or GFR to near pre-treatment values.6,7 Although recovery from short-term 
imbalances in prostaglandins is possible, chronic use of NSAIDs might cause more severe renal 
impairments, such as hepatorenal syndrome, and more permanent injuries to the kidneys. In 
addition, the co-administration of non-selective COX-inhibitors and furosemide appears to 
dampen the efficacy of furosemide, a vital diuretic in patients with compensated and 
decompensated cirrhosis and ascites. However, this effect on diuresis was not associated with 
selective COX-2 inhibitors.8  Furthermore, non-selective COX inhibitors decreased platelet 
aggregation in two studies,7,8 and corresponding changes were not large enough to be significant 
in selective COX-2 inhibitors. Inhibited platelet aggregation increases chances of bleeding, and 
more specifically esophageal variceal hemorrhage pertaining to patients with cirrhosis, portal 
hypertension, and existing esophageal varices.15 As bleeding from esophageal varices is difficult 
to treat and often results in fatality, non-selective COX inhibitors comparatively are associated 
with more risk of severe complications, despite the short course of treatment.  
 
Limitations 
Research on renal effects of NSAIDs in patients with pre-existing liver dysfunction is 
limited and was met with many challenges in identifying well-conducted studies. In fact, none of 
the available studies in the present had a design quality rated above “low” according to the 
GRADE system. The limited number of studies, small sample sizes of the studies available, and 
lack of randomization and blinding in the majority of trials limits the conclusions to be drawn 
and the strength of recommendations for clinical practice. The shortage of studies is reasonably 
expected due to the nature of the investigation revolving around a question of harm, which 
renders this topic less desirable to be repeated or conducted on a larger scale. This paper is meant 
to conduct a literature review to collect qualitative data from available studies and rate the level 
of evidence using the GRADE system, rather than pooling quantitative data from all studies after 
statistical adjustments, such as in a meta-analysis. Without further statistical manipulations, it is 
difficult to draw quantitative conclusions due to the use of different COX inhibitors, different 
dosages and intervals of dosing, and different parameters to indicate renal function (GFR, 
creatinine clearance, and adjusted creatinine clearance using the Cockcroft-Gault formula).20 
Therefore, inter-study statistical comparisons were not produced for the reasons narrated.  
 
CONCLUSION 
The safety of short-term administration of selective COX-2 inhibitors in cirrhosis is likely 
better than non-selective COX inhibitor, which constitutes a weak recommendation due to poor 
quality of evidence. Furthermore, great caution needs to be exercised in monitoring renal 
function when placing cirrhotic patients on non-selective COX inhibitors. Therefore, more well-
conducted studies are necessary to provide adjunctive evidence to support this finding. For future 
research, the role of prostaglandin supplementation while taking NSAIDs may be investigated, as 
an effort to identify possible venues to allow safer use of NSAIDs in the future for anti-
inflammatory needs in patients with cirrhosis. 
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 Table 1. List of selective COX-2 inhibitors and non-selective COX inhibitors 
 
 
 
 
 
 
  
Selective COX-2 inhibitors Non-selective COX inhibitors 
Celecoxib Diclofenac 
Valdecoxib Diflunisal 
Rofecoxib Etodolac 
 Fenoprofen 
 Flurbiprofen 
 Ibuprofen 
 Indomethacin 
 Ketoprofen 
 Ketorolac 
 Mefenamic acid 
 Meloxicam 
 Nabumetone 
 Naproxen 
 Oxaprozin 
 Piroxicam 
 Sulindac 
 Tolmetin 
Table 2. GFR, PGE2, RPF, inhibition of PA, and suppression of furosemide diuresis before and 
after treatment with celecoxib (n = 7), naproxen (n = 6), and placebo (n = 5) in Claria et al8 
 
 Celecoxib  Naproxen  Placebo 
 Before After P  Before After P  Before After P 
GFR (mL/min) 108 ± 10 105 ± 14 NS 113 ± 27 84 ± 22 <0.05 85 ± 11 93 ± 13 NS 
PGE2 (pg/min) 3609 ± 678 3278 ± 1.052 NS 11.6 ± 3.4 9.4 ± 2.9 <0.01 6523 ± 1194 10339 ± 5648 NS 
RPF (mL/min) 536 ± 60 483 ± 65 NS 592 ± 158 429 ± 106 <0.04 417 ± 62 491 ± 77 <0.01 
PA (%) 68 ± 12 71 ±18 NS 72 ± 8 47 ± 8 <0.05 69 ± 14 85 ± 3 NS 
Vfurosemide 
(mL/h) -- -- NS 561 ± 128 414 ± 107 <0.05 -- -- NS 
  
Table 3. Characteristics of reviewed studies, GRADE profile of studies involving use of 
selective COX-2 inhibitor in cirrhosis  
Quality assessment Characteristics of reviewed studies  
 Downgrade Criteria  Number of Patients 
Quality Importance 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Study 
Treatment 
(total) 
Placebo 
or no 
treatment 
(total) 
Reduction in GFR 
2 
1 RCT 
1 QES 
 Very 
serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Claria et 
al8 
9/28 9/28 
Very low Critical 
Guevara 
et al18 
9/9 0/9 
Reduction in urinary prostaglandin level 
2 
1 RCT 
1 QES 
 Very 
serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No bias 
likely 
Claria et 
al8 
9/28 9/28 
Very low Critical 
Guevara 
et al18 
9/9 0/9 
Inhibition of platelet aggregation 
1 1 RCT 
Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely 
Claria et 
al8 
9/28 9/28 Low Important 
Dampening effect on concurrent furosemide diuresis 
1 1 RCT 
Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely 
Claria et 
al8 
9/28 9/28 Low Important 
a Limitations in sample sizes and study designs: Claria et al:  n = 9 for celecoxib group, total n = 28, and 7 subjects withdrawn from study; Guevara: n = 9 without control group, no randomization, 
blinding, or report of statistical significance 
b Wide 95% confidence intervals in Guevara et al with respect to GFR and urinary prostaglandin levels 
RCT = randomized controlled trial 
QES = quasi-experimental study 
 
 
  
Table 4.  Characteristics of reviewed studies, GRADE profile of studies involving use of non-
selective COX inhibitors in cirrhosis 
 
Quality assessment Characteristics of reviewed studies  
 Downgrade Criteria  Number of Patients 
Quality Importance 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Study 
Treatment 
(total) 
Placebo 
or no 
treatment 
(total) 
Reduction in creatinine clearance 
5 
2 RCT 
3 QES 
 Very 
serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecision
b 
Serious 
inconsistenciesc 
No bias 
likely 
Claria et 
al8 
10/28 9/28 
Very low Critical 
Brater et 
al 19877 
5/5 0/5 
Daskalo-
poulos et 
al9 
15/15 0/15 
Quintero 
et al10 
5/5 0/5 
Brater et 
al 19866 
5/5 0/5 
Reduction in urinary prostaglandin level 
5 
2 RCT 
3 QES 
 Very 
serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecision
b 
No serious 
inconsistencies 
No bias 
likely 
Claria et 
al8 
10/28 9/28 
Very low Critical 
Brater et 
al 19877 
5/5 0/5 
Daskalo-
poulos et 
al9 
15/15 0/15 
Quintero 
et al10 
5/5 0/5 
Brater et 
al 19866 
5/5 0/5 
Inhibition of platelet aggregation 
2 
1 RCT 
1 QES 
Very 
serious 
limitations 
a 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely 
Claria et 
al8 
10/28 9/28 
Low Important 
Brater et 
al 19877 
5/5 0/5 
Dampening effect on concurrent furosemide diuresis 
1 1 RCT 
Serious 
limitationsa  
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely 
Claria et 
al8 
10/28 9/28 Low Important 
a Limitations in sample sizes and study designs: Claria et al:  n = 10 for Naproxen  group, total n = 28; Brater 1987: n = 5, no randomization, blinding, or control, no reported statistical significance or 
confidence intervals; Daskalopoulos: n = 15, no randomization, blinding, or control; Brater 1986: n = 5, randomized without blinding or control group, 1 subject withdrew early from study; Quintero et 
al: n = 5, no randomization, blinding, or control 
b Wide standard errors and 95% confidence intervals in Claria, Daskalopoulos, and Quintero et al 
c Significant reductions in creatinine clearance was seen with sulindac treatment in Brater 1987 and Quintero et al while no significance was found in Daskalopoulos et al 
 
 
